Key result
Pediatric COVID-19 vaccination-associated myocarditis shows a mild hospital course with ~86% early symptom resolution.
Why the study?
To characterize the clinical presentation, short-term prognosis, and myocardial tissue changes on CMR in pediatric patients with COVID-19 vaccination-associated myocarditis.
What are the clinical characteristics, short-term prognosis, and CMR findings of COVID-19 vaccination-associated myocarditis in pediatric patients?
Cohort (n=63)
Yes
What are the clinical characteristics, short-term prognosis, and CMR findings of COVID-19 vaccination-associated myocarditis in pediatric patients?
COVID-19 vaccination-associated myocarditis in adolescents has a mild clinical course with quick recovery and excellent short-term outcomes, though myocardial injury is frequently noted on CMR.
No takes yet. Share an insight, caveat, or question.
Indicates favorable short-term prognosis in pediatric vaccine myocarditis; leaves open long-term implications of frequent CMR abnormalities.
Jain et al. (2021) conducted a cohort in COVID-19 vaccination-associated myocarditis (n=63). COVID-19 mRNA vaccination vs. Multisystem inflammatory syndrome in children was evaluated on Clinical presentation, short-term prognosis, and myocardial tissue changes on CMR. Pediatric COVID-19 vaccination-associated myocarditis had a mild hospital course with no deaths and symptom resolution in 86% at 35 days, though 88% met CMR criteria for myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: